$HALB Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
https://www.accesswire.com/729400/halberd-tea...on-variant
Boosts effectiveness by 50% of commercially available Covid antibody in cocktail
JACKSON CENTER, PA / ACCESSWIRE / November 30, 2022 / Halberd Corporation's (OTC PINK:HALB) Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
The paper describes the Halberd sponsored research which resulted in an effective monoclonal antibody which has been shown to improve the potency of a commercially available antibody in a cocktail against the SARS Cov-2 Omicron variant from 65% to over 94% effectiveness.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability of our antibody to boost the effectiveness of other antibodies in cocktail against Covid-19 is a significant achievement as witnessed by the acceptance for publication of this peer reviewed article."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Halberd's scientists compared our Covid 19 antibody against six other commercially available antibodies, and Halberd's antibody was the only one of the seven antibodies checked that demonstrated an effectiveness against all strains of Covid-19. That alone demonstrates the superiority of Halberd's research team. Our laboratory experimentation successes to date prove that our extracorporeal (outside the body) treatment of bodily fluids could be the most effective methodology for the treatment of diseases in the future."
https://www.accesswire.com/729400/halberd-tea...on-variant
Boosts effectiveness by 50% of commercially available Covid antibody in cocktail
JACKSON CENTER, PA / ACCESSWIRE / November 30, 2022 / Halberd Corporation's (OTC PINK:HALB) Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
The paper describes the Halberd sponsored research which resulted in an effective monoclonal antibody which has been shown to improve the potency of a commercially available antibody in a cocktail against the SARS Cov-2 Omicron variant from 65% to over 94% effectiveness.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability of our antibody to boost the effectiveness of other antibodies in cocktail against Covid-19 is a significant achievement as witnessed by the acceptance for publication of this peer reviewed article."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Halberd's scientists compared our Covid 19 antibody against six other commercially available antibodies, and Halberd's antibody was the only one of the seven antibodies checked that demonstrated an effectiveness against all strains of Covid-19. That alone demonstrates the superiority of Halberd's research team. Our laboratory experimentation successes to date prove that our extracorporeal (outside the body) treatment of bodily fluids could be the most effective methodology for the treatment of diseases in the future."
